The US FDA should require postmarketing data on what happens when interchangeable biosimilars to the same reference product are substituted for each other, Janssen Biotech Inc. said at a Sept. 4 hearing on promoting competition and innovation in the biologics market.
Such data are needed to instill confidence in prescribers that patients who experience pharmacy-level switching between biosimilars that are interchangeable...






